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Abstract
Background: In spite of using heparin-coated extracorporeal circuits, cardiopulmonary bypass
(CPB) is still associated with an extensive thrombin generation, which is only partially suppressed
by the use of high dosages of heparin. Recent studies have focused on the origins of this thrombotic
stimulus and the possible role of retransfused suctioned blood from the thoracic cavities on the
activation of the extrinsic coagulation pathway. The present study was designed to find during CPB
an association between retransfusion of suctioned blood from the pericardium and pleural space,
containing activated factor VIIa and systemic thrombin generation.
Methods: Blood samples taken from 12 consenting patients who had elective cardiac surgery were
assayed for plasma factor VIIa, prothrombin fragment 1+2 (F1+2), and thrombin-antithrombin (TAT)
concentrations. Blood aspirated from the pericardium and pleural space was collected separately,
assayed for F1+2, TAT, and factor VIIa and retransfused to the patient after the aorta occlusion.
Results: After systemic heparinization and during CPB thrombin generation was minimal, as
indicated by the lower than base line plasma levels of F1+2, and TAT after correction for
hemodilution. In contrast, blood aspirated from the thoracic cavities had significantly higher levels
of factor VIIa, F1+2, and TAT compared to the simultaneous samples from the blood circulation (P
< 0.05). Furthermore, after retransfusion of the suctioned blood (range, 200–1600 mL) circulating
levels of F1+2, and TAT rose significantly from 1.6 to 2.9 nmol/L (P = 0.002) and from 5.1 to 37.5
µg/L (P = 0.01), respectively. The increase in both F1+2, and TAT levels correlated significantly with
the amount of retransfused suctioned blood (r  = 0.68, P  = 0.021 and r  = 0.90, P  = 0.001,
respectively). However, the circulating factor VIIa levels did not correlate with TAT and F1+2 levels.
Conclusions: These data suggest that blood aspirated from the thoracic cavities during CPB is
highly thrombogenic. Retransfusion of this blood may, therefore, promote further systemic
thrombin generation during CPB.
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Background
During CPB thrombin generation is extensive [1,2], there-
fore heparin is administered at high concentrations. The
origins of this thrombotic stimulus have been uncertain
and subject to speculation. It was reasoned that the con-
tact of the blood with the extracorporeal circuit, via the
intrinsic coagulation pathway, was the main contributor
to the increased thrombin generation [3]. Elevated levels
of activated coagulation factor XIIa during CPB supported
this theory [4]. It is, however, doubtful that the contact
activation pathway is the main source of the thrombin
generation. First, Lane and coworkers [5–7] found that tis-
sue factor (TF) is most likely the sole trigger of the coagu-
lation process during CPB. Second, Burman and
colleagues [8] found a sharp increase in thrombin genera-
tion in a patient with factor XII deficiency during closure
of an atrioseptal defect without a significant change in fac-
tor IX activation. Thus, factor XII activation is not always
indispensable for thrombin generation during CPB.
Recent improvements in biocompatibility of the extracor-
poreal circuit, such as heparin coatings, have resulted in
considerably less blood activation [9–13]. Despite these
improvements, however, we and also other investigators
reported no reduction in thrombin generation in patients
undergoing CPB with the use of a heparin-coated extracor-
poreal circuit [14–17], whereas others have found evi-
dence of some possible benefit of these surfaces on the
coagulation cascade [18].
Several investigators [19–22] have suggested that retrans-
fused suctioned blood from the pericardial cavity could be
the major source of a thrombin-generating agent. More
recently, Philippou et al. [23] demonstrated that pericar-
dium-induced activation of factor VII, due to ineffective
local heparinization, resulted in an increased thrombin
generation.
Thus, whereas previous studies suggested that blood is
activated predominantly by contact activation, more
recent studies indicate that the contribution of the mate-
rial-independent pathway of blood activation -the surgi-
cal wound itself- may be of much greater importance than
previously thought. The aim of this clinical study was to
elucidate the impact of retransfused suctioned blood from
the thoracic cavities on systemic TF-driven thrombin
generation.
Methods
Patients
Twelve adult patients, subsequently undergoing elective
combined heart valve surgery and coronary artery bypass
grafting were enrolled in this study. Informed consent was
obtained from each patient the day before the operation.
The study was approved by the local ethical and research
council. No patient had evidence of severe heart failure,
renal or hepatic dysfunction, or preoperative coagulopa-
thies. Moreover, no patient was treated with coumarin
derivates, platelet-inhibiting drugs, or nonsteroidal anti-
inflammatory agents within five days before the opera-
tion. The study patients did not receive antifibrinolytic
agents during CPB.
Anesthesia and cardiopulmonary bypass
Anesthesia was induced and maintained with weight-
related doses of fentanyl, sufentanil, midazolam, and
pancuronium. All patients had Swan-Ganz and arterial
catheters placed.
The extracorporeal circuit consisted of heparin-coated
tubing (Duraflo II, Baxter Bentley Inc., Irvine, CA, USA), a
hollow fiber membrane oxygenator (Capiox SX-18, Ter-
umo Corporation, Tokyo, Japan), a heparin-coated
venous reservoir (Duraflo II, BMR-1900, Baxter Bentley),
an arterial line filter (Pall autovent SV, Pall Biomedical
Ltd, Portsmouth, UK), and two biothyl-coated cardiot-
omy reservoirs (William Harvey H4700, C.R. Bard Inc.,
Tewsbury, MA, USA). Before connection of the extracor-
poreal circuit for CPB, each patient received 300 IU/kg
heparin (Heparin Leo, Leo Pharmaceutical Products BV,
Weesp, The Netherlands) to achieve an activated coagula-
tion time (ACT) > 480 seconds (Hemotec ACT II,
Medtronic Inc., Anaheim, CA, USA). An ACT was meas-
ured at baseline, after heparinization, and every 30 min-
utes during CPB. If necessary, additional boluses of
heparin were administered to maintain an ACT > 400 sec-
onds. After institution of cardiopulmonary bypass at a
flow rate of 2.4 L/min/m2, and after reaching a blood tem-
perature below 28°C (25–28°C), the heart was topically
cooled till fibrillation using cold saline 0.9% at 4°C. The
aorta was then crossclamped and a single dose of approx-
imately 800 ml (600–1000 ml) of St. Thomas I cardiople-
gic solution at 4°C was infused into the aortic root to
provide myocardial preservation. Topic cooling was
maintained during the infusion of the cardioplegic solu-
tion. Pulsatile perfusion was used throughout the period
of aorta crossclamping. During the conduct of CPB, aortic
root venting was separated from the cardiotomy suction
and in all cases less than 2% of the calculated flow (< 90
ml/min), using a volume pressure control unit with nega-
tive pressures less than 50 mmHg. Cardiotomy suction,
i.e. blood aspirated from the pericardium and pleural
space, was returned to a separated cardiotomy reservoir
that was clamped off. After completion of all the distal
anastomoses the cardiotomy reservoir clamp was
removed, allowing reinfusion of blood from the pericar-
dium and pleural space into the systemic circulation. After
CPB, heparin was reversed by 3 mg/kg protamine chloride
(Hoffman/Laroche BV, Mijndrecht, The Netherlands). All
pump blood was returned to the patient through theThrombosis Journal 2003, 1 http://www.thrombosisjournal.com/content/1/1/3
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aortic cannula or intravenously via infusion bags without
cell washing process or hemoconcentration.
Blood sampling
During and after the operation, blood samples were col-
lected from each patient at seven specific intervals: before
heparin administration (time point 1), 5 minutes after
heparinization before CPB (time point 2), 5 minutes after
the beginning of CPB (time point 3), 5 minutes after
release of the aortic crossclamp (time point 4), 5 minutes
after reinfusion of cardiotomy blood (time point 5), 15
minutes after protamine administration (time point 6),
and 2 hours after surgery (time point 7). Additional sam-
ples were taken from the pooled blood recollected by suc-
tion from the pericardium and pleural space into a
cardiotomy reservoir 5 minutes after the beginning of CPB
and 5 minutes after aorta occlusion, before retransfusion.
Laboratory assays
Blood samples were collected in 3.5% sodium citrate (9:1
vol/vol). Platelet-poor plasma for determination of TAT-
complexes, F1+2, and factor VIIa was obtained by centrifu-
gation at 4000 g for five minutes, and the supernatant was
centrifuged at 12000 g for ten minutes and stored at -70°C
until assayed. All samples were corrected for
hemodilution.
TAT and F1+2 levels were determined by enzyme-linked
immunosorbent assay (Dade-Behring GmbH, Schwal-
bach, Germany). Factor VIIa levels were determined by a
specific immunoassay, which has been described else-
where [23]. In short, flat-bottomed Maxisorb microtiter
plates (Nunc, Roskilde, Denmark) were coated for 2 hours
at room temperature or overnight at 4°C with 100 µL
coating buffer containing 5 µg/mL of the rabbit polyclo-
nal antibody RB-23, raised to a region of factor VII
exposed following its activation by cleavage at Arg152-
Ile153. Thereafter, the wells were blocked during 30 min-
utes at room temperature with 200 µL blocking buffer and
then rinsed 5 times with rinse buffer. The wells were incu-
bated for 2 hours at room temperature with 100 µL of a
factor VIIa containing sample and then 6 times rinsed
with the rinse solution. Finally, the amount of factor VIIa
captured by the rabbit anti-human factor VIIa antibody
RB-23 was quantified as follows: 100 µL of a solution con-
taining 1:100 diluted thromboplastin (Dade Innovin,
Baxter Diagnostics, Deerfield, IL), 10 µmol/L phospholi-
pid (20 mol% phosphatidylserine and 80 mol% phos-
phatidylcholine), 5 mmol/L Ca2+ and 250 nmol/L bovine
factor X [24] in Hepes buffer was added to the well and
incubated at 37°C. The activation of factor X was stopped
after 30 minutes by the addition of 35 µL Hepes-buffer
containing 20 mM EDTA. The amount of formed factor Xa
was measured using the chromogenic substrate S2765 as
described previously [24]. A calibration curve was con-
structed with known concentrations of recombinant fac-
tor VIIa (Novo Nordisk Pharma, Copenhagen, Denmark).
Statistical analysis
The results were expressed as the mean ± standard error of
the mean (SEM), except for the patients' demographics,
which was expressed as mean ± standard deviation.
Simultaneous samples of the cardiotomy blood and the
systemic circulation were compared by the paired Stu-
dent's t test. This statistic was also used to compare sam-
ples during and after CPB with the sample taken before
CPB and after heparin administration. Spearman's rank
correlation analysis was used to measure the relationship
between thrombin generation and the amount of retrans-
fused cardiotomy blood and circulating factor VIIa levels,
respectively. A p value less than 0.05 was considered to be
significant.
Results
Patients' demographics
The patients (9 men and 3 women) ranged in age from 50
to 76 years, and from 52 to 85 kg in weight. Table 1 gives
descriptive data for the patients, operation, and perfusion.
No patients developed bleeding complications; no
patients died.
Table 1: Patients' demographics Data are presented as mean ± standard deviation.
Gender, M / F 9 / 3
Age, years 68 ± 8
Height, cm 170 ± 8
Weight, kg 75 ± 12
Aortic crossclamp time, min (range) 66 ± 42 (21–141)
Bypass time, min (range) 98 ± 54 (41–198)
Total amount retransfused cardiotomy blood, mL (range) 617 ± 480 (200 – 1600)
Myocardial revascularization 8
Valve replacement 2
Valve replacement/repair and myocardial revascularization 2Thrombosis Journal 2003, 1 http://www.thrombosisjournal.com/content/1/1/3
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Factor VIIa
Plasma levels of factor VIIa decreased significantly during
bypass from 27.1 to 14.8 ρmol/L (Figure 1); the decreases
were significant after heparin infusion (between time
points 2 and 4). The mean factor VIIa levels from the car-
diotomy suction fluid were significantly higher than the
levels measured in the systemic circulation at the same
sampling points (time points 3 and 4) during CPB (19.7
and 20.3 ρmol/L versus 12.5 and 14.8 ρmol/L; P = 0.01
for both, respectively). After retransfusion of the cardiot-
omy blood, surprisingly, no increase in factor VIIa levels
was observed in the circulation. Hence, after protamine
administration an increase in circulating levels of factor
VIIa was noticed.
Prothrombin fragment 1+2
The marker of thrombin generation, F1+2, decreased after
heparin infusion and after start of CPB (Figure 2). The
mean plasma level of F1+2 measured in the cardiotomy
blood was significantly higher (≈ 6-fold increase) than the
levels measured at the same time points in the systemic
circulation (8.2 and 8.6 nmol/L versus 1.3 and 1.6 nmol/
L; P < 0.001 for both, respectively). After retransfusion of
the cardiotomy blood, a dramatic and significant increase
was observed in the F1+2 levels from the systemic circula-
tion until 2 hours after the operation (from 1.6 nmol/L to
3.8 nmol/L, P = 0.002). In addition, a significant correla-
tion was measured between the amount of retransfused
cardiotomy blood and the rise of plasma F1+2 levels in the
Plasma factor VIIa levels Figure 1
Plasma factor VIIa levels Plasma factor VIIa levels with time in patients undergoing CPB (● ), and in the cardiotomy blood 
(). Blood samples were taken at the various time points as described in the "Methods" section. Data are presented as mean ± 
SEM. Asterisks indicate a statistically significant difference compared with the sample before heparin administration (P < 0.05 by 
paired Student's t test); double asterisk indicate a statistically significant difference between the simultaneous samples of the 
cardiotomy blood and the systemic circulation (P < 0.05 by paired Student's t test); cross signs indicate a statistically significant 
difference compared with the sample before retransfusion of the cardiotomy blood (P < 0.05 by paired Student's t test).
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systemic circulation (r = 0.68, P = 0.021). No correlation
was detected between the circulating F1+2 levels and factor
VIIa levels, Figure 3 (r = 0.21, P = 0.08).
Thrombin-antithrombin
Plasma concentrations of TAT, a marker of the amount of
thrombin that is generated, decreased slightly after
heparin infusion and up to the phase of retransfusion of
the cardiotomy blood (Figure 4). The mean plasma con-
centration of TAT measured in the cardiotomy blood was
significantly higher (>20-fold increase) than the levels
measured at the same time points in the systemic circula-
tion (105.2 and 108.8 µg/L versus 3.5 and 5.1 µg/L; P <
0.001 for both, respectively). After retransfusion of the
cardiotomy blood, plasma TAT concentrations rose signif-
icantly in the systemic circulation (from 5.1 µg/L to 37.5
µg/L,  P  = 0.01). Thereafter, the plasma TAT levels
remained significantly elevated until 2 hours after the
operation (P  < 0.05). Moreover, close correlation was
measured between the amount of retransfused cardiot-
omy blood and the rise of plasma TAT levels in the sys-
temic circulation (r = 0.90, P = 0.001). No correlation was
detected between the circulating TAT levels and factor VIIa
levels, Figure 5 (r = 0.12, P = 0.32).
Plasma levels of prothrombin fragment 1+2 Figure 2
Plasma levels of prothrombin fragment 1+2 Plasma levels of F1+2 with time in patients undergoing CPB (● ), and in the 
cardiotomy blood (). Blood samples were taken at the various time points as described in the "Methods" section. Data are 
presented as mean ± SEM. Asterisks indicate a statistically significant difference compared with the sample before heparin 
administration (P < 0.05 by paired Student's t test); double asterisk indicate a statistically significant difference between the 
simultaneous samples of the cardiotomy blood and the systemic circulation (P < 0.001 by paired Student's t test); cross signs 
indicate a statistically significant difference compared with the sample before retransfusion of the cardiotomy blood (P < 0.05 
by paired Student's t test).
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Discussion
To diminish allogeneic blood transfusions and volume
loss in the extracorporeal circulation, retransfusion of suc-
tioned blood from the thoracic cavities during CPB is con-
sidered a salutary technique. However, recent reports have
highlighted the quality of this blood and its relative role
on the activation of the extrinsic coagulation pathway
[23,25,26]. In the present study we found evidence that
blood aspirated from the pericardium and pleural space is
highly thrombogenic, because of an excellent correlation
between the amount of retransfused blood and the
increased levels of TAT and F1+2. The origin of ongoing
thrombin generation is most likely caused by the presence
of TF rather than factor VIIa in the blood aspirated from
the pericardium and pleural space [27].
Triggering of the in vivo coagulation is thought to require
complex formation between TF and factor VIIa to form an
activation complex that converts factor IX and X into the
serine proteases factor IXa and Xa, respectively. Factor Xa
is the enzyme that ultimately generates thrombin [28].
Chung and associates [21] showed that blood mononu-
clear cells taken from the pericardium express twice the
level of TF compared with cells taken simultaneously from
the systemic circulation. In addition, in vivo thrombin
generation is at least partly mediated by cell-derived
microparticles containing TF [29]. In this study we found
that blood aspirated from the thoracic cavities had signif-
icantly higher levels of factor VIIa compared to the simul-
taneous samples from the systemic circulation. Because TF
is an essential cofactor for factor VIIa generation [28],
high factor VIIa levels in blood aspirated from the pericar-
Correlation between factor VIIa and F1+2 Figure 3
Correlation between factor VIIa and F1+2 Correlation between circulating factor VIIa levels and F1+2 levels in patients 
undergoing CPB.
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dium and pleura space reflects the presence of significant
amounts of TF.
Accordingly to the presence of TF in the blood aspirated
from the thoracic cavities, corresponding elevations in
markers of direct thrombin generation were observed. In
addition, this study is the first to provide direct evidence
that the amount of retransfused cardiotomy blood vol-
ume contributes to the level of thrombin generation dur-
ing CPB. Close correlation was established between the
amount of retransfused cardiotomy blood and the rise of
plasma TAT levels and F1+2 levels in the systemic circula-
tion. Retransfusion of an amount as minimal as 200 mL
cardiotomy blood already resulted in a systemic increase
of 8% in plasma TAT concentrations and 0.4% in plasma
F1+2 concentrations. These results confirm the suggestions
and findings of others that the general practice of retrans-
fusion of cardiotomy blood is a potential source of acti-
vated hemostatic components [20–23,25,26]. A possible
explanation for the high activation marker levels in the
blood aspirated from the thoracic cavities might be poor
local anticoagulation. It has been reported that pericardial
blood had lower levels of heparin than corresponding
perfusate samples, and the levels of heparin in samples
from the thoracic cavities correlated inversely with those
of thrombin generation markers and factor VIIa [23].
Thrombin-antithrombin plasma concentrations Figure 4
Thrombin-antithrombin plasma concentrations TAT plasma concentrations with time in patients undergoing CPB (● ), 
and in the cardiotomy blood (). Blood samples were taken at the various time points as described in the "Methods" section. 
Data are presented as mean ± SEM. Asterisks indicate a statistically significant difference compared with the sample before 
heparin administration (P < 0.05 by paired Student's t test); double asterisk indicate a statistically significant difference between 
the simultaneous samples of the cardiotomy blood and the systemic circulation (P < 0.001 by paired Student's t test); cross 
signs indicate a statistically significant difference compared with the sample before retransfusion of the cardiotomy blood (P < 
0.05 by paired Student's t test).
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Alternatively, it is tempting to speculate that the concen-
tration of the natural inhibitor of the TF/factor VIIa com-
plex, tissue factor pathway inhibitor (TFPI), in the
suctioned blood is greatly reduced, which in turn greatly
amplifies thrombin generation. Additional anticoagula-
tion of the cardiotomy blood seems thus required. The
notion that anticoagulation must be focused on inhibit-
ing TF-driven blood coagulation is also supported by the
observation that local administration of aprotinin, an
inhibitor of the intrinsic blood coagulation, in the tho-
racic cavities did not prevent generation of highly proco-
agulant mediators in blood aspirated from these cavities
[30].
Conclusions
In conclusion, we demonstrated that blood aspirated
from the pericardium and pleural space is highly throm-
bogenic, and retransfusion of this blood may promote
systemic thrombin generation during CPB. Therefore, as
been pointed out by others [19,20,22,25,26], this blood
should be discarded or processed with a cell salvage sys-
tem prior to retransfusion.
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